Vicarious Surgical is developing a next-generation surgical robotics platform with single-incision capabilities. Pre-commercial; speculative exposure to the next surgical robotics architecture.
A sell-side note highlighted RBOT as one of the cleanest second-order plays on the AI infrastructure buildout. The thesis is non-consensus; the math is starting to back it.
TSLA crossed consensus on both revenue and EPS, then lifted full-year guidance citing accelerating AI infrastructure demand. The print resets the bar for the rest of the cohort.
RBOT data via the Bluechip ingestion pipeline (currently mock-mode). Editorial copy from the Bluechip universe.@BluechipsAI·October 10, 2026